MoonLake Immunotherapeutics, a clinical-stage biopharmaceutical company, engages in developing therapies. It is developing Sonelokimab, a novel investigational Nanobody therapy for the treatment of inflammation. The company is involved in conducting Phase II trials for hidradenitis suppurativa, psoriatic arthritis, ankylosing spondylitis, or radiographic axial spondyloarthritis. MoonLake Immunotherapeutics was founded in 2021 and is headquartered in Zug, Switzerland.

Company Data

Name MoonLake Immunotherapeutics - Class A Ordinary Shares

Company MoonLake Immunotherapeutics

Symbol MLTX

Website https://www.moonlaketx.com

Primary Exchange

NASDAQ

ISIN KY61559X1045

Asset Class Share

Sector Healthcare

Industry Biotechnology

CEO Jorge Santos da Silva

Market Capitalization 3 Mrd.

Country Switzerland

Currency USD

Employees 0,1 T

Address Dorfstrasse 29, 6300 Zug

IPO Date 2020-10-20

ID Changes

Date	From	To
06.04.2022	HLXA	MLTX

Ticker Symbols

Name	Symbol
NASDAQ	MLTX

More Shares

Investors who hold MoonLake Immunotherapeutics - Class A Ordinary Shares also have the following shares in their portfolio:

CREDIT AGRICOLE CORP & INV BANK CALL ZERO CPN NTS 11/08/30 Bond

NHK SPRING CO LTD Share

The financial platform MoneyPeak tracks and analyzes investments and portfolios. From securities portfolios to crypto purchases.
Useful, simple, and free. Stocks, ETFs, ETCs, ETNs, indices, funds, bonds, certificates, currencies, options, rights issue.

Imprint Data Protection Blog Community Feedback Changelog